Apotex looking to sell about $1 billion in shares in initial public offering
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $1.44 a week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $5.77 plus GST every four weeks. After 52 weeks, price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
TORONTO – Drug company Apotex Health Corp. says it is looking to sell about $1 billion worth of shares in its initial public offering.
The company says it expects to sell between 41.7 million and 50 million shares at a price between $20 and $24 per share.
The plan includes the sale of between 35.4 million and 42.5 million shares in a treasury offering by the company valued at a total of about $850 million.
It also includes a secondary offering of between 6.25 million and 7.5 million shares by certain shareholders valued at a total of about $150 million.
The selling shareholders are also expected to grant an over-allotment option to the underwriters for up to an additional 6.25 million to 7.5 million shares at the offering price
Apotex, which has applied to list the shares on the Toronto Stock Exchange, has a broad portfolio of generic drugs and consumer health products.
This report by The Canadian Press was first published June 1, 2026.
Advertisement Advertise With Us